Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAequs

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy these 2 midcaps, 1 largecap in a staggered manner for the medium term

      Sumit Bilgaiyan of Equity99 feels valuation looks attractive but sentiment still remains uncertain

    • Looking for momentum plays? Top three stocks which could give 15-23% return in 6 months

      We expect Nifty to extend its consolidation phase over the next few weeks in the broad range of 11,650-11,200 amidst the stock specific action, says Dharmesh Shah of ICICI Direct.com Research

    • Nifty to consolidate amid IIP, WPI data; top 3 stocks to bet on

      Sumit Bilgaiyan of Equity99 expects the Nifty to consolidate between last week’s high-low levels

    • 3 pharmaceutical sweet spots that could return 13-34% in 1 year

      Post-correction, pharmaceutical companies are now available at reasonable valuations making them attractive to long term investors

    • Global brokerages upgrade these 6 stocks to buy post Q4 results

      Global brokerage houses have upgraded a few stocks, highlighting robust Q4 FY18 results. Moneycontrol takes a look at six such stocks which have seen a ratings upgrade

    • Podcast | See Nifty at 11K in the short-term if 10,706 holds; these 5 buys may offer 15% return

      Here is a list of top five stocks which could give up to 15% return in the short term.

    • Buy or Sell: Top stock trading ideas by Achin Goel & Rajesh Agarwal for May 3

      Rajesh Agarwal of AUM Capital recommends buying Container Corporation of India with stop loss at Rs 1300 and target at Rs 1357, a buy in EIH with stop loss at Rs 182 and target at Rs 200 and a buy also in Kansai Nerolac Paints with stop loss at Rs 493 and target at Rs 520.

    • Buy or sell: Top stock trading ideas by Dharmesh Shah, Prakash Gaba & Rajesh Agarwal

      Dharmesh Shah of ICICIdirect.com recommends buying Bajaj Finserv with target at Rs 6095 and stop loss at Rs 5190 and has a buy also on Munjal Showa with target at Rs 269 and Stop loss at Rs 208.

    • Remain focused on companies with exposure to Indian markets: IIFL

      IIFL has published a report on pharmaceutical companies and it specifically analyses US business margins. In an interview to CNBC_TV18, Abhishek Sharma, Vice President and Pharma Analyst at IIFL spoke about the latest happenings in the sector.

    • Hold Alkem Laboratories: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may hold Alkem Laboratories.

    • Buy, Sell, Hold: 5 stocks and 1 sector are on analysts’ radar today

      Voltas, Alkem Labs, among others, are being tracked by investors on Thursday.

    • Use every rise to short Nifty; 3 stocks which can give up to 11% return in short term

      We have witnessed strong call unwinding and fresh short built up in the index as results index touched 10100 levels and recommend investors to keep a more stock specific approach rather than focusing too much on the index. We also recommend investors to use every rise in the market as shorting opportunity until trading below 10230, said Rohit Singre of Bonanza Portfolio.

    • Top 10 fundamentally strong stocks to buy on dips which could give up to 22% return

      Most experts have a target of 32,000 – 33,000 on the S&P BSE Sensex which translates into an upside of about 5 percent. Investors will be better off staying with stocks which can outperform markets by a wide margin.

    • Here are a few pharma stock ideas from HDFC Sec's Amey Chalke

      In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities shared his readings and outlook on specific pharmaceutical stocks.

    • Top buzzing stocks to trade on January 12

      Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today -- Idea Cellular, Sun Pharma, DRL, Lupin, Aurobindo Pharma , Glenmark, Natco Pharma, Alkem Labs, Ajanta Pharma, Strides Shasun, Biocon, Cipla, Cyient, MMTC and Power Grid.

    • Buy, sell, hold: 11 stocks that analysts are watching out today

      Nomura has a buy ratings on Dr Reddy‘s, Glenmark, Alkem, Cadila and Jubilant Life. It says Teva‘s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA. Teva expects mid-single digit price erosion in the base US business.

    • Here are a few investment ideas from Prakash Diwan

      In an interview to CNBC-TV18, Prakash Diwan of Altamount Capital Management shared his readings and outlook on specific stocks and sectors.

    • Prefer Glenmark, Alembic Pharma, Alkem Labs: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that one may prefer Glenmark Pharma, Alembic Pharma and Alkem Laboratories.

    • Buy Alkem Laboratories on every dip: Avinash Gorakshakar

      Avinash Gorakshakar, Market Expert suggests buying Alkem Laboratories on every dip.

    • Buy Alkem Laboratories, says SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may Alkem Laboratories and one should book profits in Dr Lal Pathlab.

    • Nirmal Bang says hold Dr Lal for long-term, like Alkem too

      Runjhun Jain, Senior Research Analyst, Nirmal Bang is bullish on both Dr Lal Pathlabs and Alkem Laboratories.

    • Accumulate RComm at lower levels: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher recommends accumulating Reliance Communication at lower levels.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347